Humacyte Inc (HUMA)
Healthcare
Biotechnology
0.65 $
-2.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Humacyte Inc (HUMA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 72.7% of the shares are freely tradable; institutional investors hold 22.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
22.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
7.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
72.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
270Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 5.55 | 12,316,955 | +8.6 | 03/31/2026 |
| Vanguard Group Inc | 3.79 | 8,416,971 | +11.9 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.22 | 7,158,162 | +0.0 | 03/31/2026 |
| Antipodes Partners Limited | 2.58 | 5,723,750 | +49,039.3 | 03/31/2026 |
| Great Point Partners LLC | 1.69 | 3,750,000 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.65 | 3,658,108 | -1.7 | 03/31/2026 |
| State Street Corp | 1.37 | 3,043,929 | +7.3 | 03/31/2026 |
| UBS Group AG | 1.25 | 2,782,070 | -6.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.74 | 5,295,966 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 2.06 | 3,971,971 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.